2020年歐洲腫瘤內(nèi)科學(xué)會(ESMO)年會將于9月14日-10月18日在線上召開，其中9月19日-21日的science weekend將有眾多腫瘤領(lǐng)域新數(shù)據(jù)公布。作為歐洲最負(fù)盛名及最具影響力的腫瘤學(xué)會議，本次會議將展示腫瘤學(xué)的最新進(jìn)展，搭建學(xué)術(shù)研究與臨床實踐溝通的橋梁。
作為中國創(chuàng)新藥物研發(fā)的先行者與領(lǐng)跑者，恒瑞醫(yī)藥多款研發(fā)藥物再次登錄國際舞臺，治療領(lǐng)域涵蓋消化道腫瘤、肺癌、骨肉瘤、乳腺癌、頭頸部腫瘤、血液腫瘤、婦科腫瘤等多個領(lǐng)域。
今天，先讓我們一睹為快，看看有哪些研究即將亮相！
ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced non-squamous non-small-cell lung cancer patients with activating EGFR mutations: a multicentered, randomized,double-blind,placebo-controlled phase IIItrial (CTONG1706)甲磺酸阿帕替尼一線聯(lián)合吉非替尼治療晚期EGFR 突變NSCLC 的III期臨床研究
1267P - Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC
卡瑞利珠單抗聯(lián)合阿帕替尼二線治療晚期鱗狀NSCLC
報告形式：E-Poster
講者：Guanghui ?Gao(Shanghai,China)? ??
1366P - Efficacy? and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer? with EGFR-TKI resistance (date updated)? ? ?
阿帕替尼聯(lián)合EGFR-TKI治療EGFR-TKI耐藥后的晚期NSCLC(數(shù)據(jù)更新)講者：Ruifen ?Tian(Taiyuan, China)
1804P - The Efficacy of Apatinib plus Topotecan as Laterline Therapy for Advanced Small Cell Lung Cancer阿帕替尼聯(lián)合拓?fù)涮婵底鳛橥砥谛〖?xì)胞肺癌后線治療療效?講者：Haifeng Qin(Beijing, China)? ??
1805P - Apatinib? combined with irinotecan in the treatment of small cell lung cancer: a phase? 2, single-arm, prospective study
阿帕替尼聯(lián)合伊立替康治療小細(xì)胞肺癌：II期、單臂、前瞻性研究?講者：Yanbin ?Zhao(Harbin, China)
983P-Camrelizumab(C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): an open-label, multi-center, phase 2 trial.卡瑞利珠單抗聯(lián)合阿帕替尼治療晚期肝細(xì)胞癌(RESCUE)：開放標(biāo)簽、多中心、II期研究講者：Jianming ?Xu(Beijing, China)
985P - A phase 2 study of camrelizumab for advanced hepatocellular carcinoma: two-year outcomes and continued treatment beyond RECIST-defined progression.卡瑞利珠單抗治療晚期肝細(xì)胞癌的II期研究：RECIST定義進(jìn)展后持續(xù)治療2 年結(jié)果講者：Zhenggang Ren(Shanghai, China)
81TiP - The? changes? of? immune? function? and? prognosis in advanced perihilar? cholangiocarcinoma? patients? by immunotherapy? combined? with different topical therapies免疫療法聯(lián)合其他類型治療晚期肝門型膽管細(xì)胞癌患者的免疫功能及預(yù)后改變講者：Chao Zhao(Taiyuan,China)
1452P - Phase I study of apatinib plus POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-na?ve advanced gastric cancer (TNAGC), the result including the dose level (dl) at 850mg阿帕替尼聯(lián)合POF( 紫杉醇+FOLFOX) 治療初治晚期胃癌患者(TNAGC) 的I 期研究，包含850mg 劑量的結(jié)果?講者：Rongbo Lin(Fuzhou, Fujian, China)??
1455P - A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer阿帕替尼聯(lián)合化療二線治療晚期胃癌患者的單臂、開放標(biāo)簽、前瞻性、多中心研究講者：Jifeng Feng(Nanjing, China)
1428P - Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: a prospective clinical study(data updated)阿帕替尼聯(lián)合多西他賽二線治療晚期胃癌：前瞻性臨床研究(數(shù)據(jù)更新)講者：Mudan Yang(Taiyuan, China)
1434P - A prospective, multicenter, nonrandomized,controlled trial of Apatinib plus perioperative chemotherapy with FLOT protocol and surgery for the treatment of stage III gastric cancer阿帕替尼聯(lián)合FLOT方案圍手術(shù)期化療及手術(shù)治療III期胃癌的前瞻性多中心非隨機(jī)對照研究講者：Jun Zhang(Shenyang, China)
442P - Camrelizumab combined with Apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer ：One-arm exploratory clinical trial卡瑞利珠單抗聯(lián)合阿帕替尼治療晚期胃癌和結(jié)直腸癌：單臂探索性臨床研究講者：Li Xiao(Xiamen, China)
1427P - A phase II study of neoadjuvant concurrent chemoradiotherapy with apatinib for HER-2 negative Siewert type II and III adenocarcinoma of esophagogastric junction新輔助同步放化療聯(lián)合阿帕替尼治療Siewert II型、Ⅲ型HER2陰性胃食管交界處腺癌的II期臨床研究講者：Qun Zhao(Shijiazhuang, China)
1431P - Study on the safety and efficacy of apatinib combined with concurrent chemoradiotherapy in the treatment of nonoperative esophageal cancer阿帕替尼聯(lián)合同步放化療治療不可切除食管癌患者的療效和安全性講者：Jingping Yu(Changzhou, China)
1501TiP - The changes of tumor immune microenvironment in esophageal squamous cell carcinoma patients intervened by different neoadjuvant therapies應(yīng)用不同的新輔助方案治療食管鱗癌的腫瘤免疫微環(huán)境的改變講者：Wei Li Wang(Taiyuan, China)?
1034P - Camrelizumab in the Treatment of Patients with local advanced/metastatic esophageal squamous cell carcinoma (ESCC)：a multi-center, prospective, cohort study卡瑞利珠單抗治療局部晚期/轉(zhuǎn)移性食管鱗癌(ESCC)：多中心、前瞻性隊列研究講者：Qun Y. Zhu(Su zhou, China)
1503TiP - A Prospective Study of Apatinib in Combination with Neoadjuvant Concurrent Chemoradiotherapy for locally Advanced Esophageal Squamous Cell Carcinoma??阿帕替尼聯(lián)合同步放化療新輔助治療局部晚期食管鱗癌的前瞻性研究講者：Jun Wang(Shijiazhuang, China)
224P - Neoadjuvant? pyrotinib plus trastuzumab, docetaxel, and carboplatin in patients with? HER2-positive early breast cancer: a single-group, multicenter, phase 2 study?吡咯替尼聯(lián)合曲妥珠單抗、多西他賽、卡鉑新輔助治療HER2陽性乳腺癌患者：單臂、多中心、II期研究講者：Zhenzhen ?Liu(Zhengzhou, China)
225P - Phase 2 study of pyrotinib plus albumin-bound paclitaxel and trastuzumab as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer吡咯替尼聯(lián)合白蛋白紫杉醇和曲妥珠單抗新輔助治療HER2陽性早期或局部晚期乳腺癌的II期研究講者：Ting Luo(Chengdu, Sichuan, China)
294P - Pyrotinib and capecitabine for HER2–Positive metastatic breast cancer patients with previously untreated brain metastases: A single-group multicenter phase II study吡咯替尼聯(lián)合卡培他濱治療既往未經(jīng)治療腦轉(zhuǎn)移的HER2陽性轉(zhuǎn)移性乳腺癌患者：單臂、多中心、II期研究講者：Min Yan(Zhengzhou, China)?
270P - Apatinib added to taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: a multicenter, randomized, phase II,open-label trial阿帕替尼聯(lián)合紫杉類和鉑類用于三陰性和HER2陽性乳腺癌的新輔助治療：多中心、隨機(jī)、II期、開放標(biāo)簽研究講者：Yunjiang ?J. Liu(Shijiazhuang, China)?
15P - Study on the mechanism of apatinib reversing tamoxifen resistance in breast cancer?阿帕替尼逆轉(zhuǎn)乳腺癌中他莫昔芬耐藥性的機(jī)制研究講者：Qingxia ?Li(Shijiazhuang, China)
A Randomized Multicentered Phase 3 Study to Evaluate Apatinib in Subjects with Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer阿帕替尼治療局部晚期或轉(zhuǎn)移性放射性碘治療分化型甲狀腺癌：多中心隨機(jī)III期研究
912MO - A single-arm, open-label, multicenter phase 2 study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥ 2 lines of chemotherapy: CAPTAIN study卡瑞利珠單抗治療接受過2 線及以上化療后進(jìn)展的復(fù)發(fā)/ 轉(zhuǎn)移性鼻咽癌(NPC)患者的單臂、開放標(biāo)簽、多中心、Ⅱ期研究：CAPTAIN講者：Li Zhang(Guangzhou, China)
941P - Efficacy and Safety of Apatinib Combined with Capecitabine in Patients with Advanced Nasopharyngeal Carcinoma阿帕替尼聯(lián)合卡培他濱治療晚期鼻咽癌的療效和安全性講者：XiuYu Cai(Guangzhou, China)
893MO - An open-label, single-center,phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma卡瑞利珠單抗聯(lián)合阿帕替尼治療復(fù)發(fā)/ 難治性外周T細(xì)胞淋巴瘤的開放標(biāo)簽、單中心、II期、單臂研究?講者：Yan Xie(Beijing, China)? ?
Efficacy and safety of HHPG-19K for prophylaxis of chemotherapy-induced neutropenia in patients with lymphoma硫培非格司亭用于化療導(dǎo)致粒細(xì)胞減少的淋巴瘤患者的療效和安全性講者：Liping Su(Shanxi, China)
840P - Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: an open-label, multicenter phase II study法米替尼聯(lián)合卡瑞利珠單抗治療鉑類耐藥的卵巢/ 輸卵管/ 原發(fā)性腹膜癌和晚期宮頸癌：開放標(biāo)簽、多中心、II期研究講者：Lingfang Xia(Shanghai, China)
1646P - Apatinib for treatment of inoperable metastatic or locally advanced chondrosarcoma: What we can learn about the biological behavior of chondrosarcoma from a multicenter study阿帕替尼治療不可手術(shù)的轉(zhuǎn)移或局部晚期軟骨肉瘤講者：Lu Xie(Beijing, China)
1511P - A real world study of pyrotinib in patients with HER-2 positive/mutations tumors excluding breast cancer吡咯替尼治療HER2 陽性/ 突變腫瘤(乳腺癌除外)的真實世界研究?講者：Jun Qian(Suzhou, China)
38P - Study on human plasma concentration andserosal permeation of oral apatinib mesylate講者：Jian Shi(Shijiazhuang, China)注：以上預(yù)告內(nèi)容為ESMO官網(wǎng)截至2020/08/11的最新信息，如需詳細(xì)內(nèi)容至ESMO官網(wǎng)查閱。
聯(lián)眾醫(yī)藥網(wǎng)公眾號
聯(lián)眾藥械圈小程序
聯(lián)眾客服微信號
